Loading
Vivani Medical, Inc. Stock: price and insider trades · United States
US·Mcap US$101M
No insider purchase over the last 90 days. The latest was filed 16 Jul 2026.
Vivani Medical, Inc.: what insiders have been doing
Vivani Medical, Inc. is a listed company. Filings by its managers are published through SEC (Form 4). Between 18 October 2025 and 18 October 2026, 2 insiders published 10 filings.
Not one open-market sale was filed. On the buying side, 1 insider reported 9 purchases totalling €16.2M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Those buying include 1 senior executive. The largest single trade was a purchase of €5.2M by Williams Gregg, published on 28 October 2025.
The last insider purchase was made public on 16 July 2026, 93 days ago. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. For comparison, the SEC allows two business days to file a Form 4.
For context, the typical company on the same exchange (median of 5,458 companies) published 22 filings over the same period, against 10 filings here. Looking back to 2016, when coverage begins, insiders filed 83 purchases and no sales. The 10-K for the year ended 31 December 2025 shows -26.6 m USD of net income.
Elsewhere in the same market, our signals recently picked up insider purchases at GameStop Corp. and Heico Corp. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
93
Thresholds
n/a
Buy Volume
€26M
83 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleGregg Williams18 buys
Donald Dwyer2 buys
Since the insiders bought
- +2.3%Entry US$1.32 · Close at T+30 US$1.35
- +6.9%Entry US$1.01 · Close at T+365 US$1.08
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.12
Analyst consensus
3 analysts1.33/5
US$3.50Target US$3.83(+242%)US$4.00
Income statement
Gross profitUS$111.9k
EBITDA-US$27.1M
Net income-US$26.6M0.0% margin
Valuation
P/Book5.3x
Beta3.30
Balance sheet & cash
Market capUS$101M
Total debtUS$18.9M
Free Cash Flow-US$25.5M
Debt / Equity94%
Profitability & ownership
ROE-220.4%
ROA-48.5%
% insiders55.4%
% institutions5.9%
Last declaration on 16 July 2026
Declarations93 total
793,650 shares@ US$1.260.90% mcap3.6% of flowCommon StockSEC:0001753926-26-001192:0
Canonical exit: 13 Oct 2026 (T+90)
1,587,301 shares@ US$1.261.51% mcap7.0% of flowCommon StockSEC:0001753926-26-000672:0
Canonical exit: 14 Jul 2026 (T+90)
1,310,680 shares@ US$1.034.8% of flowCommon StockSEC:0001753926-26-000475:0
Canonical exit: 13 Jun 2026 (T+90)
1,601,941 shares@ US$1.035.7% of flowCommon StockSEC:0001753926-26-000323:0
Canonical exit: 16 May 2026 (T+90)
1,351,351 shares@ US$1.486.9% of flowCommon StockSEC:0001753926-26-000196:0
Canonical exit: 27 Apr 2026 (T+90)
1,473,214 shares@ US$1.125.8% of flowCommon StockSEC:0001753926-26-000145:0
Canonical exit: 15 Apr 2026 (T+90)
20,000 shares0Common StockSEC:0001753926-25-002003:0
1,473,214 shares@ US$1.125.8% of flowCommon StockSEC:0001753926-25-001892:0
Canonical exit: 15 Mar 2026 (T+90)
1,473,214 shares@ US$1.125.8% of flowCommon StockSEC:0001753926-25-001808:0
Canonical exit: 13 Feb 2026 (T+90)
3,703,703 shares@ US$1.6221.2% of flowCommon StockSEC:0001753926-25-001658:0
Canonical exit: 25 Jan 2026 (T+90)
1,473,214 shares@ US$1.125.8% of flowCommon StockSEC:0001753926-25-001616:0
Canonical exit: 13 Jan 2026 (T+90)
1,473,215 shares@ US$1.125.8% of flowCommon StockSEC:0001753926-25-001511:0
Canonical exit: 14 Dec 2025 (T+90)
3,499 shares@ US$1.010.0% of flowCommon StockSEC:0001753926-25-000860:0
Canonical exit: 12 Aug 2025 (T+90)
1,113 shares@ US$1.010.0% of flowCommon StockSEC:0001554855-25-000391:0
Canonical exit: 23 Jul 2025 (T+90)
1,569 shares@ US$1.010.0% of flowCommon StockSEC:0001753926-25-000675:0
Canonical exit: 20 Jul 2025 (T+90)
18,529 shares@ US$1.020.1% of flowCommon StockSEC:0001753926-25-000620:0
Canonical exit: 8 Jul 2025 (T+90)
34,000 shares@ US$0.990.1% of flowCommon StockSEC:0001753926-25-000596:0
Canonical exit: 3 Jul 2025 (T+90)
2,000 shares@ US$1.010.0% of flowCommon StockSEC:0001753926-25-000583:0
Canonical exit: 1 Jul 2025 (T+90)
4,000 shares@ US$1.0258.8% of flowCommon StockSEC:0001753926-25-000555:0
Canonical exit: 30 Jun 2025 (T+90)
1,000 shares@ US$1.112.5% of flowCommon StockSEC:0001753926-25-000392:0
Canonical exit: 29 May 2025 (T+90)
3,968,253 shares@ US$1.2619.0% of flowCommon StockSEC:0001753926-24-001875:0
Canonical exit: 6 Feb 2025 (T+90)
1,000 shares@ US$1.142.4% of flowCommon StockSEC:0001753926-24-001643:0
Canonical exit: 30 Dec 2024 (T+90)
2,000 shares@ US$0.964.1% of flowCommon StockSEC:0001753926-24-001334:0
Canonical exit: 20 Feb 2024 (T+90)
5,000 shares@ US$1.2413.2% of flowCommon StockSEC:0001753926-24-001335:0
Canonical exit: 28 Oct 2024 (T+90)
1,078 shares@ US$1.010.0% of flowCommon StockSEC:0001753926-24-000345:0
Canonical exit: 15 May 2024 (T+90)
25 of 93 declarations
About Vivani Medical, Inc.
Vivani Medical, Inc. is a company focused on developing innovative medical devices. It specializes in solutions for the treatment of chronic diseases.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
